Overview

There were many lessons to be learned from existing immunisation strategies, particularly in Africa. The implementation of routine immunisation using monovalent and/or multivalent vaccines that target other serogroups in Africa is constantly changing, dissemination of such lessons will be of great importance globally.

There were many lessons to be learned from existing immunisation strategies, particularly in Africa. The implementation of routine immunisation using monovalent and/or multivalent vaccines that target other serogroups in Africa is constantly changing, dissemination of such lessons will be of great importance globally.

The Global Meningococcal Initiative (GMI) was formed in 2009 with the goal of preventing MD through education, research, international cooperation and the development of vaccines.

The Global Meningococcal Initiative (GMI) was formed in 2009 with the goal of preventing MD through education, research, international cooperation and the development of vaccines.

The initiative was formed in 2009 with the goal of preventing MD through education, research, international cooperation and the development of vaccines.

The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of MD in children under 5 years of age in Chile (Figure 3).

The increase in the proportion of cases due to outbreaks of serogroup W is of considerable concern. The number of MD cases associated with serogroup W has increased from 10 in 1999 to 36 in 2013 in Chile (Figure 4).

The number of cases attributable to serogroup W has increased from two in 2010 to 2011.

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).

Experience of routine immunisation against MD caused by serogroup C

In Brazil, in 2010, serogroup C accounted for 86% of the cases of MD. The introduction of MenC conjugate vaccine into the routine vaccination programme in 2010 provided an immediate reduction in incidence rates of serogroup C in children under 5 years of age (Figure 3).